Apr 08, 2008 06:30 ETNextGen Acquires Patent Application for Breast
Cancer Stem Cell Treatment
LONDON, UNITED KINGDOM--(Marketwir
Bioscience, Inc. ("NextGen") (PINK SHEETS:NXGB)
company that develops novel therapeutic proteins that disrupt the
advance of life-threatening cancers, today announced it has acquired
use, commercialisation and ownership rights of a patent application
for the treatment of cancer from Oxon Life Science Inc.
The patent application describes an improved method of identifying
and purifying undifferentiated stem cells from solid breast
carcinomas that are normally resistant to conventional therapies. The
cancer stem cell is typically represented as a distinct population of
cells within a tumour which may remain even if the rest of the tumour
is destroyed, through chemotherapy, or other anti-cancer therapies.
This may lead to the subsequent re-occurrence of the cancer at a
later date, a relapse, which is devastating for the patient. These
cancer stem cells, precursors of cancer, possess certain
characteristics, which can be targeted to allow identification.
NextGen CEO, Konstantinos Kardiasmenos, stated, "Based on evidence
that cancers such as breast cancer and prostate cancer proliferate
primarily from cancer stem cells, this technology will be vital for
both early diagnosis and identifying targets for a new generation of
targeted therapeutic strategies."
"Acquiring the patent application for this innovative biotechnology
is an exciting early step in its progress toward commercialisation,
he said.
About NextGen Bioscience Inc.
NextGen is positioning itself as the world's leading bioscience
company in the development and commercial licensure of novel
therapeutic proteins that disrupt the advance of life-threatening
cancers. The company leverages cutting-edge research collaborations
to achieve breakthroughs in anti-cancer treatments, and then licenses
these patented drug product candidates to Big Pharmaceutical and
Biotechnology companies.
At present, NextGen is rapidly building its portfolio of proprietary
biotechnology. NextGen's target market --cancer treatments-- is the
largest disease market, exploding at a 20% growth rate each year.
NextGen's treatment niche is based on recent discoveries that
indicate that most tumors may be derived from a single cancer-
initiating cell population which has stem cell properties (a cancer
stem cell). NextGen has chosen to concentrate on identification of
certain cell-specific characteristics, making it possible to identify
precursor cells of tumors, and then conduct a more
extensive 'fingerprinting' profile that will enable the development
of cell-specific anti-cancer treatments. This will result in
a 'tailor made' cancer treatment strategy that is superior to
existing therapies in its ability to eradicate malignant cells whilst
leaving healthy tissue intact.
Statements about NextGen's future expectations and all other
statements in this press release other than historical facts
are "forward-looking statements" within the meaning of section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as the term is defined in the Private Litigation
Reform Act of 1995. NextGen's actual results could differ materially
from expected results. NextGen undertakes no obligation to update
forward-looking statements to reflect subsequently occurring events
or circumstances.
For more information about NextGen Bioscience Inc., or to schedule an
interview with Mr. Kardiasmenos, please contact Investor Relations at
+44 20 7247 8186 or investorrelations@
For more information, please contact
NextGen Bioscience, Inc.
Konstantinos Kardiasmenos
+44 (0) 20 7247 8186
+44 (0) 20 7377 9454 (FAX)
Email: investorrelations@
Website: www.nextgenbioscien
http://www.marketwi
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
No comments:
Post a Comment